SCHEMBL2300618

SCHEMBL2300618

O=C1c2ccccc2C(=O)c2c([N+](=O)[O-])ccc(O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
POLB P06746 3/20 1.00
APEX1 P27695 2/20 1.00
CASP6 P55212 1/20 1.00
CSNK2A2 P19784 1/20 0.79
CSNK2B P67870 1/20 0.79
CSNK2A1 P68400 1/20 0.79
CSNK2A3 Q8NEV1 1/20 0.79
CYP3A4 P08684 6/20 0.77
HPGD P15428 4/20 0.77
SMN1; SMN2 Q16637 3/20 0.77
HIF1A Q16665 3/20 0.77
TSHR P16473 3/20 0.77
TP53 P04637 2/20 0.77
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
MAOA P21397 4/20 0.66
S100A4 P26447 2/20 0.57
PTPRC P08575 1/20 0.57
MCL1 Q07820 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5109566 0.89 MAPT (0.79) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL29644991 0.89 CSNK2A2 (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL16656215 0.89 CSNK2A2 (0.88) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL11135123 0.89 CSNK2A2 (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL3519179 0.89 CSNK2A2 (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL28116340 0.87 CSNK2A2 (0.86) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL3501895 0.87 TSHR (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL10356144 0.87 TSHR (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL186885 0.87 TSHR (1.00) MAPTPOLBAPEX1CASP6CSNK2A2
SCHEMBL10356103 0.87 TSHR (1.00) MAPTPOLBAPEX1CASP6CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119297188-A Preparation method of nanosheet-organic active molecule-catalyst hybrid material and application of nanosheet-organic active molecule-catalyst hybrid material in photoelectric storage integrated battery 中国科学院大连化学物理研究所 2025-01-10 CN claimed
CN-119253090-A Zn-I2Battery electrolyte and preparation method and application thereof 中国科学院大连化学物理研究所 2025-01-03 CN claimed
EP-0021264-B1 PROCESS FOR THE DELIGNIFICATION OF LIGNOCELLULOSIC MATERIALS BAYER AG (DE) 1983-01-19 EP claimed
CN-119253090-A Zn-I2Battery electrolyte and preparation method and application thereof 中国科学院大连化学物理研究所 2025-01-03 CN disclosed
EP-2537186-A1 USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS BASF SE (DE) 2012-12-26 EP disclosed
CN-102844886-A Use of indanthrene compounds in organic photovoltaics BASF SE 2012-12-26 CN disclosed
US-20110203649-A1 USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS BASF SE (DE) 2011-08-25 US disclosed
WO-2011101810-A1 USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS BASF SE (DE) 2011-08-25 WO disclosed
US-7722784-B2 Liquid crystal composition, liquid crystal device, reflection display material, light modulating material, and anthraquinone compound FUJIFILM CORPORATION (JP) 2010-05-25 US disclosed
US-7722784-B2 Liquid crystal composition, liquid crystal device, reflection display material, light modulating material, and anthraquinone compound FUJIFILM CORPORATION (JP) 2010-05-25 US disclosed
US-7722784-B2 Liquid crystal composition, liquid crystal device, reflection display material, light modulating material, and anthraquinone compound FUJIFILM CORPORATION (JP) 2010-05-25 US disclosed
CN-1379763-A Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions SIGNAL PHARM INC (US) 2002-11-13 CN disclosed
EP-1218347-A1 PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS SIGNAL PHARMACEUTICALS, INC. (US) 2002-07-03 EP disclosed
WO-2001012609-A1 PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS SIGNAL PHARMACEUTICALS, INC. (US) 2001-02-22 WO disclosed
EP-0103095-B1 DICHROIC MATERIAL CONTAINING ANTHRAQUINONE DYES BAYER AG (DE) 1990-08-29 EP disclosed
EP-0103095-A2 Dichroic material containing anthraquinone dyes BAYER AG (DE) 1984-03-21 EP disclosed
EP-0021264-B1 PROCESS FOR THE DELIGNIFICATION OF LIGNOCELLULOSIC MATERIALS BAYER AG (DE) 1983-01-19 EP disclosed
US-4350566-A DIGESTION; WOOD PULPING; PAPERMAKING BAYER AKTIENGESELLSCHAFT (DE) 1982-09-21 US disclosed
EP-0021264-A1 Process for the delignification of lignocellulosic materials BAYER AG (DE) 1981-01-07 EP disclosed
US-4006171-A FROM NITROANTHRAQUINONE AND HALOGEN BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110203649-A1 USE OF INDANTHRENE COMPOUNDS IN ORGANIC PHOTOVOLTAICS ICMT, EPCAM, INF2 MAPT 266/4885POLB 2736/4885APEX1 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.